…
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Utah Medical Products (UTMD) makes specialized airway-management medical devices sold mainly to hospitals and distributors. Long-term growth drivers include aging demographics, steady clinical demand for respiratory care, incremental product upgrades and modest international expansion. Investors may find the company attractive because it operates in a narrow, specialized market with recurring demand and apparent operating scale in its niche.
Material risks include product and customer concentration, regulatory and reimbursement changes, competition from larger device makers and execution or supply-chain disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 14.11M | 16.80M | 20.09M | 20.66M | 19.06M |
| Net income | 11.29M | 13.87M | 16.64M | 16.47M | 15.18M |
| Selling general administrative | 9.93M | 3.67M | 11.02M | 10.41M | 10.10M |
| Selling and marketing expenses | - | 1.90M | 1.69M | 1.51M | 1.41M |
| Gross profit | 19.88M | 24.14M | 30.04M | 32.20M | 30.92M |
| Reconciled depreciation | 3.01M | 2.85M | 7.08M | 7.08M | 7.28M |
| Ebit | 14.11M | 16.80M | 18.38M | 12.71M | 18.88M |
| Ebitda | 17.06M | 19.57M | 24.75M | 19.79M | 30.92M |
| Depreciation and amortization | 2.95M | 2.77M | 6.37M | 7.08M | 12.04M |
| Non operating income net other | - | - | - | 0.21M | 0.01M |
| Operating income | 11.40M | 13.59M | 16.78M | 12.71M | 18.88M |
| Other operating expenses | 27.12M | 27.31M | 33.45M | 32.49M | 18.14M |
| Interest expense | - | - | - | -0.87M | 4.18M |
| Tax provision | 2.82M | 2.93M | 3.76M | 4.19M | 4.27M |
| Income tax expense | 2.82M | 2.93M | 3.45M | 4.19M | 4.27M |
| Total revenue | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Total operating expenses | 8.47M | 10.55M | 13.26M | 12.41M | 12.04M |
| Cost of revenue | 18.64M | 16.76M | 20.19M | 20.09M | 18.14M |
| Total other income expense net | 2.71M | 3.21M | 3.31M | 7.95M | 0.18M |
| Net income from continuing ops | 11.29M | 13.87M | 16.90M | 20.66M | 19.06M |
| Net income applicable to common shares | - | - | - | 16.47M | 14.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 122.54M | 122.54M | 135.46M | 123.87M | 115.56M |
| Intangible assets | 0.84M | 2.87M | 4.95M | 10.38M | 17.31M |
| Other current assets | 0.53M | 0.45M | 0.43M | 0.52M | 0.46M |
| Total liab | 3.27M | 5.11M | 7.14M | 9.62M | 8.42M |
| Total stockholder equity | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
| Deferred long term liab | - | - | - | 0.55M | 0.58M |
| Other current liab | 1.69M | 3.21M | 3.57M | 4.54M | 2.84M |
| Common stock | 0.03M | 0.03M | 0.04M | 0.04M | 0.04M |
| Capital stock | 0.03M | 0.03M | 0.04M | 0.04M | 0.04M |
| Retained earnings | 128.65M | 129.30M | 138.34M | 126.01M | 115.31M |
| Other liab | - | - | - | 3.32M | 4.49M |
| Good will | 14.05M | 13.58M | 13.69M | 13.35M | 14.10M |
| Other assets | - | - | 0.00M | - | -0.00M |
| Cash | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total current liabilities | 2.60M | 3.76M | 4.71M | 5.75M | 3.60M |
| Current deferred revenue | - | - | 0.33M | - | - |
| Net debt | -85.53M | -82.69M | -92.53M | -74.71M | -60.64M |
| Short term debt | - | - | 0.05M | - | - |
| Short long term debt total | 0.23M | 0.28M | 0.34M | 0.34M | 0.33M |
| Other stockholder equity | 119.27M | -11.91M | 0.59M | 0.25M | 0.84M |
| Property plant equipment | - | - | - | 10.22M | 10.99M |
| Total current assets | 97.74M | 96.33M | 106.27M | 89.92M | 73.16M |
| Net tangible assets | - | - | - | 90.52M | 75.73M |
| Short term investments | - | - | 185.74M | - | - |
| Net receivables | 3.52M | 4.09M | 3.39M | 5.54M | 5.13M |
| Inventory | 7.93M | 8.81M | 9.58M | 8.81M | 6.60M |
| Accounts payable | 0.91M | 0.54M | 0.77M | 1.22M | 0.76M |
| Accumulated other comprehensive income | -9.42M | - | -10.66M | -12.04M | -9.05M |
| Common stock total equity | - | - | - | 0.04M | 0.04M |
| Retained earnings total equity | - | - | - | 126.01M | 115.31M |
| Non currrent assets other | - | - | -0.00M | -1.51M | -2.10M |
| Non current assets total | 24.80M | 26.21M | 29.19M | 33.95M | 42.40M |
| Capital lease obligations | 0.23M | 0.28M | 0.29M | 0.34M | 0.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.21M | -0.59M | -0.82M | -0.55M |
| Change to liabilities | - | - | - | 0.72M | 0.69M |
| Total cashflows from investing activities | -0.37M | - | - | -0.82M | -0.55M |
| Total cash from financing activities | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
| Change to operating activities | - | - | - | 0.17M | 0.59M |
| Net income | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
| Change in cash | 2.78M | -9.89M | 17.82M | 14.08M | 9.38M |
| Begin period cash flow | 82.98M | 92.87M | 75.05M | 60.97M | 51.59M |
| End period cash flow | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total cash from operating activities | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Depreciation | 3.01M | 2.85M | 6.37M | 7.08M | 7.28M |
| Other cashflows from investing activities | - | - | - | -0.01M | -0.86M |
| Dividends paid | 3.98M | 4.26M | 4.28M | 3.16M | 11.46M |
| Change to inventory | 1.20M | 0.59M | -0.67M | -2.35M | -0.48M |
| Change to account receivables | 0.33M | -0.83M | 2.27M | -0.51M | -1.09M |
| Sale purchase of stock | -8.36M | -19.97M | -2.50M | -2.50M | -6.98M |
| Other cashflows from financing activities | - | 0.39M | 0.12M | -0.82M | 13.80M |
| Change to netincome | - | - | - | -0.18M | 0.14M |
| Capital expenditures | 0.37M | 0.23M | 0.64M | 0.82M | 0.55M |
| Change receivables | - | - | - | -0.53M | -1.13M |
| Cash flows other operating | - | - | - | -0.01M | -0.08M |
| Exchange rate changes | - | - | - | - | -0.36M |
| Cash and cash equivalents changes | - | - | - | 14.85M | 9.38M |
| Change in working capital | 0.32M | -1.80M | -0.23M | -2.23M | -1.01M |
| Stock based compensation | 0.37M | 0.26M | 0.23M | 0.18M | 0.17M |
| Other non cash items | 0.37M | -0.00M | -0.03M | 0.04M | 0.06M |
| Free cash flow | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| UTMD Utah Medical Products Inc |
-1.66 2.25% |
71.97 | 22.75 | 13.04 | 6.58 | 1.85 | 3.84 | 10.90 |
| ISRG Intuitive Surgical Inc |
3.70 0.84% |
443.59 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-8.90 4.32% |
197.19 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
1.64 1.66% |
100.55 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
2.32 1.08% |
218.03 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
7043 South 300 West, Midvale, UT, United States, 84047-1048
801 566 1200
140
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin L. Cornwell | Chairman, CEO, Pres & Sec. | 1947 |
| Mr. Brian L. Koopman | Principal Financial Officer, Accounting Mang. & Controller | 1970 |
| Mark L. Fox | VP of Marketing | NA |
| Mr. Kevin L. Cornwell | Chairman, CEO, President & Secretary | 1947 |
| Mr. Brian L. Koopman | Principal Financial Officer, Accounting Manager & Controller | 1970 |
| Mark L. Fox | Vice President of Marketing | NA |
| Marcena H. Clawson | Head of Corporate Sales | NA |
| Marcena H. Clawson | Vice President of Corporate Sales | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.